May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
A Breast Cancer Risk Assessment Tool That Includes Breast Density Measures
Distinct Molecular Tumor Profile in Younger CRC Patients Recognized
Dr Ira Klein Discusses the Use of Fee-for-Service in Oncology